A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.
作者信息
Besse Lenka, Besse Andrej, Mendez-Lopez Max, Vasickova Katerina, Sedlackova Miroslava, Vanhara Petr, Kraus Marianne, Bader Jürgen, Ferreira Renan B, Castellano Ronald K, Law Brian K, Driessen Christoph
机构信息
Experimental Oncology and Hematology, Department of Oncology and Hematology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
Experimental Oncology and Hematology, Department of Oncology and Hematology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland.
出版信息
Haematologica. 2019 Sep;104(9):e415-e419. doi: 10.3324/haematol.2018.207704. Epub 2019 Feb 21.
Abstract
摘要
相似文献
1
A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.蛋白酶体抑制剂耐药性多发性骨髓瘤中的代谢转换确保了更高的线粒体代谢、蛋白质折叠和鞘磷脂合成。
Haematologica. 2019 Sep;104(9):e415-e419. doi: 10.3324/haematol.2018.207704. Epub 2019 Feb 21.
2
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.XPO1抑制剂与硼替佐米或卡非佐米联合治疗可诱导IκBα的核定位，并克服人多发性骨髓瘤中获得性蛋白酶体抑制剂耐药性。
Oncotarget. 2016 Nov 29;7(48):78896-78909. doi: 10.18632/oncotarget.12969.
3
Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.用于研究多发性骨髓瘤中蛋白酶体抑制剂耐药机制和克服策略的新型细胞系模型。
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1666-1676. doi: 10.1016/j.bbadis.2019.04.003. Epub 2019 Apr 4.
4
Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.抑制L-谷氨酰胺转运体ASCT2可使浆细胞骨髓瘤细胞对蛋白酶体抑制剂敏感。
Cancer Lett. 2021 Jun 1;507:13-25. doi: 10.1016/j.canlet.2021.02.020. Epub 2021 Mar 10.
5
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.新型β2选择性蛋白酶体抑制剂LU-102与硼替佐米和卡非佐米协同作用，克服骨髓瘤细胞对蛋白酶体抑制剂的耐药性。
Haematologica. 2015 Oct;100(10):1350-60. doi: 10.3324/haematol.2014.109421. Epub 2015 Jun 11.
6
Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.蛋白酶体抑制剂诱导 SIRT1 去乙酰化 GLI2 以增强多发性骨髓瘤中的 hedgehog 信号转导活性和耐药性。
Oncogene. 2020 Jan;39(4):922-934. doi: 10.1038/s41388-019-1037-6. Epub 2019 Oct 1.
7
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.EZH2和EZH1的双重抑制使PRC2依赖性肿瘤对蛋白酶体抑制敏感。
Clin Cancer Res. 2017 Aug 15;23(16):4817-4830. doi: 10.1158/1078-0432.CCR-16-2735. Epub 2017 May 10.
8
A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.一种临床相关的脉冲处理生成了一种硼替佐米耐药的骨髓瘤细胞系，该细胞系缺乏蛋白酶体突变，并且对 Bcl-2 抑制剂 venetoclax 敏感。
Sci Rep. 2022 Jul 27;12(1):12788. doi: 10.1038/s41598-022-17239-3.
9
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.多发性骨髓瘤中的蛋白酶体抑制：目前可用的蛋白酶体抑制剂的头对头比较。
Cell Chem Biol. 2019 Mar 21;26(3):340-351.e3. doi: 10.1016/j.chembiol.2018.11.007. Epub 2019 Jan 3.
10
Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.分子伴侣GRP78增强聚集体向自噬体的转运以促进多发性骨髓瘤的耐药性。
Oncotarget. 2015 Feb 20;6(5):3098-110. doi: 10.18632/oncotarget.3075.
引用本文的文献
1
Non-Canonical, Strongly Selective Protein Disulfide Isomerases as Anticancer Therapeutic Targets.非经典、强选择性蛋白质二硫键异构酶作为抗癌治疗靶点
Biomolecules. 2025 Aug 8;15(8):1146. doi: 10.3390/biom15081146.
2
Flavonoids and Sesquiterpene Lactones from (Arnica-Do-Cerrado) and Their In Vitro Effects on Multiple Myeloma and Acute Myeloid Leukemia.来自（巴西草原山金车）的黄酮类化合物和倍半萜内酯及其对多发性骨髓瘤和急性髓系白血病的体外作用。
Metabolites. 2025 Aug 9;15(8):542. doi: 10.3390/metabo15080542.
3
Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma.蛋白质稳态工作负荷对多发性骨髓瘤中蛋白酶体抑制剂敏感性的影响
Clin Exp Med. 2025 May 26;25(1):176. doi: 10.1007/s10238-025-01713-z.
4
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma.骨髓基质细胞间的隧道纳米管支持骨髓瘤中的线粒体自噬及抗凋亡作用。
Blood Cancer J. 2025 Jan 9;15(1):3. doi: 10.1038/s41408-025-01210-2.
5
MiR-34c-5p Inhibition Affects Bax/Bcl2 Expression and Reverses Bortezomib Resistance in Multiple Myeloma Cells.微小RNA-34c-5p抑制影响多发性骨髓瘤细胞中Bax/Bcl2表达并逆转硼替佐米耐药性
Indian J Hematol Blood Transfus. 2024 Oct;40(4):596-603. doi: 10.1007/s12288-024-01742-w. Epub 2024 Apr 11.
6
Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.多发性骨髓瘤获得硼替佐米耐药：从机制到策略。
Curr Treat Options Oncol. 2024 Nov;25(11):1354-1365. doi: 10.1007/s11864-024-01273-6. Epub 2024 Oct 21.
7
Toll-like receptor signaling in multiple myeloma cells promotes the expression of pro-survival genes B-cell lymphoma 2 and MYC and modulates the expression of B-cell maturation antigen.Toll 样受体信号在多发性骨髓瘤细胞中促进了生存基因 B 细胞淋巴瘤 2 和 MYC 的表达，并调节了 B 细胞成熟抗原的表达。
Front Immunol. 2024 Jun 7;15:1393906. doi: 10.3389/fimmu.2024.1393906. eCollection 2024.
8
A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.一种新型的威特综合征相关蛋白激活剂，具有血液系统恶性肿瘤的抗肿瘤活性。
Haematologica. 2024 Nov 1;109(11):3602-3614. doi: 10.3324/haematol.2022.282672.
9
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome.NSD2通过将一碳代谢导向表观基因组，驱动t(4;14)骨髓瘤细胞对腺苷酸激酶2的依赖。
Blood. 2024 Jul 18;144(3):283-295. doi: 10.1182/blood.2023022859.
10
Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.蛋白酶体抑制剂与 NF-κB 通路在白血病和淋巴瘤中的相互作用：蛋白酶体抑制剂面临挑战的综合述评。
Cell Commun Signal. 2024 Feb 8;22(1):105. doi: 10.1186/s12964-023-01433-5.
本文引用的文献
1
The Influence of Metabolism on Drug Response in Cancer.代谢对癌症中药物反应的影响
Front Oncol. 2018 Nov 2;8:500. doi: 10.3389/fonc.2018.00500. eCollection 2018.
2
Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma.蛋白二硫键异构酶家族抑制剂用于多发性骨髓瘤的治疗。
Leukemia. 2019 Apr;33(4):1011-1022. doi: 10.1038/s41375-018-0263-1. Epub 2018 Oct 12.
3
Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.硫氧还蛋白抑制激活线粒体自噬，克服多发性骨髓瘤对硼替佐米的适应性耐药。
J Hematol Oncol. 2018 Feb 27;11(1):29. doi: 10.1186/s13045-018-0575-7.
4
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.多发性骨髓瘤中的硼替佐米耐药与丝氨酸合成增加有关。
Cancer Metab. 2017 Aug 29;5:7. doi: 10.1186/s40170-017-0169-9. eCollection 2017.
5
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.谷氨酰胺酶抑制剂CB-839与卡非佐米在耐药多发性骨髓瘤细胞中具有协同作用。
Oncotarget. 2017 May 30;8(22):35863-35876. doi: 10.18632/oncotarget.16262.
6
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.非经典SQSTM1/p62-Nrf2信号通路激活通过氧化还原、代谢和翻译重编程介导多发性骨髓瘤细胞对蛋白酶体抑制剂的耐药性。
Oncotarget. 2016 Oct 11;7(41):66360-66385. doi: 10.18632/oncotarget.11960.
7
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.难治性/复发性多发性骨髓瘤的比较蛋白质组学分析揭示了与硼替佐米治疗耐药相关的生物标志物。
Oncotarget. 2016 Aug 30;7(35):56726-56736. doi: 10.18632/oncotarget.11059.
8
Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.细胞内谷胱甘肽决定了硼替佐米对多发性骨髓瘤细胞的细胞毒性。
Blood Cancer J. 2016 Jul 15;6(7):e446. doi: 10.1038/bcj.2016.56.
9
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.蛋白酶体抑制剂适应性骨髓瘤细胞在很大程度上不依赖蛋白酶体活性，并显示出复杂的蛋白质组学变化，特别是在氧化还原和能量代谢方面。
Leukemia. 2016 Nov;30(11):2198-2207. doi: 10.1038/leu.2016.102. Epub 2016 Apr 27.
10
Myeloma today: Disease definitions and treatment advances.多发性骨髓瘤现状：疾病定义和治疗进展。
Am J Hematol. 2016 Jan;91(1):90-100. doi: 10.1002/ajh.24236.
Zotero 插件